Health authorities in the UK have initiated a recall of several batches of Napralief, a widely used painkiller, citing significant patient safety concerns. The Medicines and Healthcare products Regulatory Agency (MHRA) announced the recall of this anti-inflammatory drug, which is a brand name for naproxen, due to missing vital information in its Patient Information Leaflet (PIL).

Napralief is commonly available at major retailers such as Boots and Superdrug and is prescribed or used by thousands of Britons to alleviate pain associated with conditions like arthritis, gout, period pain, and various muscle or bone inflammations. The recall specifically impacts batches with codes B51496, B51497, and B51102, all manufactured by Omega Pharma Limited.

The core issue revolves around critical omissions in the patient leaflet, which could lead to unsafe medication use. Most notably, the leaflet fails to include a crucial warning against exceeding three tablets in a single day, a directive essential for preventing accidental overdose. Furthermore, precise dosage instructions were absent. The MHRA highlighted that the leaflet should clearly state that on the first day of treatment, patients should take two tablets initially, followed by one tablet 6-8 hours later. For the second and third days, if treatment is still required, one 250mg tablet should be taken every 6-8 hours.

Beyond dosage and overdose warnings, other vital health advisories were also missing. Patients were not informed to seek an eye examination if they develop vision disturbances, nor were they cautioned that serious allergic reactions can occur even in individuals with no prior history of allergy to painkillers. Another significant omission was the advice for patients to inform their doctor if blood or urine tests are needed, as this might necessitate stopping treatment 48 hours beforehand.

The MHRA also specified that the affected leaflets lacked information regarding heart problems and associated risk factors, certain autoimmune or mixed connective tissue diseases, and potential serious skin reactions. Dr. Alison Cave, MHRA Chief Safety Officer, underscored the importance of comprehensive and accurate safety information, stating, "As a result of these omissions, patients may not receive the full information required to use the medicine safely."

Despite these omissions, Dr. Cave affirmed that "Napralief 250mg is considered safe when used in line with the correct dosage instructions." She reassured patients that small, unintentional dosing mistakes are usually not harmful, but proper guidance is paramount. For patients currently holding affected batches, the MHRA provided the correct usage instructions: take two tablets on the first day, followed by one tablet 6-8 hours later. For the second and third day of treatment, if needed, one tablet should be taken every 6–8 hours. Crucially, Napralief should not be taken for more than three consecutive days.

Patients who have experienced any adverse effects after taking Napralief are strongly advised to seek medical advice immediately and to report their experiences through the MHRA's Yellow Card scheme, which monitors the safety of medicines and medical devices. Meanwhile, healthcare professionals across the UK have been instructed to cease the sale of the identified affected batches and to ensure all remaining stock is returned to their respective suppliers.